Plasma estradiol levels and antidepressant effects of omega-3 fatty acids in pregnant women.

Animals Antidepressive Agents Docosahexaenoic Acids Eicosapentaenoic Acid Estradiol Fatty Acids, Omega-3 Female Humans Plasma Pregnancy Pregnant Women Rats

Journal

Brain, behavior, and immunity
ISSN: 1090-2139
Titre abrégé: Brain Behav Immun
Pays: Netherlands
ID NLM: 8800478

Informations de publication

Date de publication:
03 2020
Historique:
received: 17 12 2018
revised: 12 02 2019
accepted: 14 02 2019
pubmed: 19 2 2019
medline: 28 4 2021
entrez: 19 2 2019
Statut: ppublish

Résumé

Omega-3 polyunsaturated fatty acids (PUFAs) reduce depressive symptoms through an anti-inflammatory effect, and injection of both omega-3 PUFAs and estradiol (E2) induces antidepressant-like effects in rats by regulating the expression of inflammatory cytokines. The aims of this study were to examine the association of increased E2 during pregnancy with depressive symptoms and with inflammatory cytokines in women who were and were not supplemented with omega-3 PUFAs. Pregnant women with Edinburgh Postnatal Depression Scale scores ≥9 were recruited at 12-24 weeks of gestation. The participants were randomly assigned to receive 1800 mg omega-3 fatty acids (containing 1206 mg eicosapentaenoic acid [EPA]) or placebo for 12 weeks. E2, omega-3 PUFAs, high-sensitivity C-reactive protein, interleukin-6, and adiponectin were measured at baseline and at the 12-week follow-up. Multivariable regression analyses were conducted to examine the association of the changes of E2 and omega-3 PUFAs with the changes in depressive symptoms and with the changes of inflammatory cytokines at follow-up by intervention group. Of the 108 participants in the trial, 100 (92.6%) completed the follow-up assessment including blood sampling. Multivariable regression analyses revealed that the increase of EPA and E2 was significantly associated with a decrease in depressive symptoms among the participants assigned to the omega-3 group, but not among those assigned to the placebo group. Neither E2 nor any PUFAs were associated with a change in inflammatory cytokines. Supplementation with EPA and increased levels of E2 during pregnancy might function together to alleviate antenatal depression through a mechanism other than anti-inflammation.

Sections du résumé

BACKGROUND
Omega-3 polyunsaturated fatty acids (PUFAs) reduce depressive symptoms through an anti-inflammatory effect, and injection of both omega-3 PUFAs and estradiol (E2) induces antidepressant-like effects in rats by regulating the expression of inflammatory cytokines. The aims of this study were to examine the association of increased E2 during pregnancy with depressive symptoms and with inflammatory cytokines in women who were and were not supplemented with omega-3 PUFAs.
METHODS
Pregnant women with Edinburgh Postnatal Depression Scale scores ≥9 were recruited at 12-24 weeks of gestation. The participants were randomly assigned to receive 1800 mg omega-3 fatty acids (containing 1206 mg eicosapentaenoic acid [EPA]) or placebo for 12 weeks. E2, omega-3 PUFAs, high-sensitivity C-reactive protein, interleukin-6, and adiponectin were measured at baseline and at the 12-week follow-up. Multivariable regression analyses were conducted to examine the association of the changes of E2 and omega-3 PUFAs with the changes in depressive symptoms and with the changes of inflammatory cytokines at follow-up by intervention group.
RESULTS
Of the 108 participants in the trial, 100 (92.6%) completed the follow-up assessment including blood sampling. Multivariable regression analyses revealed that the increase of EPA and E2 was significantly associated with a decrease in depressive symptoms among the participants assigned to the omega-3 group, but not among those assigned to the placebo group. Neither E2 nor any PUFAs were associated with a change in inflammatory cytokines.
CONCLUSION
Supplementation with EPA and increased levels of E2 during pregnancy might function together to alleviate antenatal depression through a mechanism other than anti-inflammation.

Identifiants

DOI: 10.1016/j.bbi.2019.02.014 PMID: 30776476
pubmed: 30776476
pii: S0889-1591(18)31218-2
doi: 10.1016/j.bbi.2019.02.014
pii:
doi:

Substances chimiques

Antidepressive Agents 0
Fatty Acids, Omega-3 0
Docosahexaenoic Acids 25167-62-8
Estradiol 4TI98Z838E
Eicosapentaenoic Acid AAN7QOV9EA

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

29-34

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Daisuke Nishi (D)

Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan; Department of Mental Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Mental Health Policy, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan. Electronic address: d-nishi@umin.ac.jp.

Kuan-Pin Su (KP)

Department of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Electronic address: cobolsu@gmail.com.

Kentaro Usuda (K)

Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan; Department of Mental Health Policy, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.

Jane Pei-Chen Chang (JP)

Department of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Kei Hamazaki (K)

Department of Public Health, Faculty of Medicine, University of Toyama, Toyama, Japan.

Tamaki Ishima (T)

Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan.

Yo Sano (Y)

Toda Chuo Women's Hospital, Saitama, Japan.

Hiroe Ito (H)

Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan.

Keiich Isaka (K)

Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan.

Yoshiyuki Tachibana (Y)

Division of Infant and Toddler Mental Health, Department of Psychosocial Medicine, Japan.

Shinji Tanigaki (S)

Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan; Department of Obstetrics and Gynecology, Kyorin University School of Medicine, Tokyo, Japan.

Tomo Suzuki (T)

Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.

Kenji Hashimoto (K)

Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan.

Yutaka J Matsuoka (YJ)

Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan; Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Plasma estradiol levels and antidepressant...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Antidépresseurs › Plasma estradiol levels and antidepressant...
questionsmedicales.fr › Lipides › Huiles › Huiles de poisson › Acides gras omega-3 › Acide docosahexaénoïque › Plasma estradiol levels and antidepressant...
questionsmedicales.fr › Lipides › Huiles › Huiles de poisson › Acides gras omega-3 › Acide eicosapentanoïque › Plasma estradiol levels and antidepressant...
questionsmedicales.fr › Hormones gonadiques › Hormones sexuelles stéroïdiennes › Congénères de l'oestradiol › Oestradiol › Plasma estradiol levels and antidepressant...
questionsmedicales.fr › Lipides › Huiles › Huiles de poisson › Acides gras omega-3 › Plasma estradiol levels and antidepressant...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Plasma estradiol levels and antidepressant...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Sang › Plasma sanguin › Plasma estradiol levels and antidepressant...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Reproduction › Grossesse › Plasma estradiol levels and antidepressant...
questionsmedicales.fr › Personnes › Femmes › Femmes enceintes › Plasma estradiol levels and antidepressant...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Plasma estradiol levels and antidepressant...